NEW YORK (GenomeWeb News) – Genewiz and the John Theurer Cancer Center at Hackensack University Medical Center today announced a collaboration for the discovery of ovarian cancer biomarkers.

The deal is aimed at identifying biomarkers from ovarian cancer samples that can be used to predict a patient's prognosis, as well as the outcomes from chemotherapy treatments. The cancer center will supply the samples for analysis at Genewiz's CLIA laboratory in South Plainfield, NJ.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.